New York, October 28, 2022 — Pfizer Inc. (NYSE: PFE) announced today that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded their assessment of Janus kinase (JAK) inhibitors authorized for the treatment of certain inflammatory diseases in the European Union (EU) and has provided updated recommendations for their use.
Science Will Win, one of Pfizer’s premiere podcasts, is back! This season we’ll explore the advancements and the challenges of cancer treatments, particularly in the breast cancer space. In this special two-part series, we’re looking at how the increasingly innovative medications used to treat cancer come to be.
NEW YORK, October 20, 2022 - Pfizer Inc. (NYSE:PFE) today announced that that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend a single dose of PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine) to help protect adults previously vaccinated with PREVNAR 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) or both PREVNAR 13® and PPSV23 against invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in PREVNAR 20®.
NEW YORK and MAINZ, Germany, October 19, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization (MA) for a 3-µg dose of COMIRNATY® (COVID-19 vaccine, mRNA), which is based on the wild-type spike protein of SARS-CoV-2, as a three-dose series for children ages 6 months to less than 5 years (also referred to as 6 months through 4 years of age).
Right now, we’re experiencing a greater emphasis on virtual working. All types of teams are moving to digital platforms, and in doing so are translating in-person working relationships to virtual experiences.
There was a classic study carried out by Dr. Albert Mehrabian in the 1960s. He claimed that only 7% of human communication was based on the spoken word. 38% of the message relied on tone of voice, while 55% was focused on body language.
Emotions are a powerful thing. They play a significant role in everything we do. And, unfortunately, there’s no off switch. What if those emotions are negative? And what if you’re at work when you start to feel angry, anxious, sad or frustrated? We need to find a way to take control, so we can still focus and get things done in this ever-changing, often stressful, world of work.
Maybe it’s at work, maybe at parties, or PTA meetings, networking events, or social clubs, but the chances are you have first-hand experience of the topic we’re covering today. How do we know this? Because it’s a very natural human phenomenon that affects most, if not all, of us: the pressure to conform.
Do you ever feel tired? Between work, family life, and hobbies, as well as keeping up with chores and other responsibilities, it’s easy to feel like life is just too busy. Right now, while life looks different for most of us in light of COVID-19, disrupted schedules and priorities which need to be juggled have added to stress levels for many of us. As well as managing your time, it’s important to understand how to manage your energy. After all, energy is what keeps us going.
When people are asked what they value in an employer, increasingly they prioritize a positive working culture. Of course, not all cultures are alike, and every business will have its nuances. But essentially, culture is a code of conduct and ethics that defines the way things are done, the way you communicate, and the things that really matter. And for a culture to thrive, trust between colleagues is essential.